Use of bioinformatics to predict MHC ligands and T-cell epitopes. Application to epitope-driven vaccine design

Methods in Microbiology

Volumn 37, Issue C, 2010, Pages 35-66

  Groot, Anne S De ^a,b   Cohen, Tobias ^a   Ardito, Matthew ^a   Moise, Lenny ^a,b   Martin, Bill ^a   Berzofsky, Jay A ^c  

^a EpiVax Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77957748704     PISSN: 05809517     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0580-9517(10)37003-6     Document Type: Book

References (150)

1. Ahlers J.D., Belyakov I.M., Thomas E.K., Berzofsky J.A. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J. Clin. Invest. 2001, 108(11):1677-1685.
2. Ahlers J.D., Takeshita T., Pendelton D., Berzofsky J.A. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. U.S.A 1997, 94(20):10856-10861.
3. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274(5284):94-96.
4. Altuvia Y., Schueler O., Margalit H. Ranking potential binding peptides to MHC molecules by a computational threading approach. J. Mol. Biol. 1995, 249(2):244-250.
5. An L.L., Whitton J.L. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. J Virol. 1997, 71(3):2292-2302.
6. An L.L., Whitton J.L. Multivalent minigene vaccines against infectious disease. Curr. Opin. Mol. Ther. 1999, 1(1):16-21.
7. Appella E., Padlan E.A., Hunt D.F. Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. EXS 1995, 73:105-119.
8. Arruda L.B. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J. Immunol. 2006, 177:2265-2275.
9. Berzofsky J.A. Epitope selection and design of synthetic vaccines. Molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. Ann. N. Y. Acad. Sci. 1993, 690:256-264.
10. Berzofsky J.A., Ahlers J.D., Derby M.A., Pendleton C.D., Arichi T., Belyakov I.M. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections. Immunol. Rev. 1999, 170:151-172.
11. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 2001, 1(3):209-219.
12. Boehncke W.H., Takeshita T., Pendleton C.D., Houghten R.A., Sadegh-Nasseri S., Racioppi L., Berzofsky J.A., Germain R.N. The importance of dominant negative effects of amino acid side chain substitution in peptide-MHC molecule interactions and T cell recognition. J. Immunol. 1993, 150(2):331-341.
13. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., Wiley D.C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364(6432):33-39.
14. Brusic V., Bajic V.B., Petrovsky N. Computational methods for prediction of T-cell epitopes-a framework for modelling, testing, and applications. Methods 2004, 34(4):436-443.
15. Brusic V., Rudy G., Harrison L.C. Prediction of MHC binding peptides using artificial neural networks. Complex Systems, Mechanisms of Adaption 1994, 253-260. IOS Press, Amsterdam. R.J. Stonier, X.S. Yu (Eds.).
16. Brusko T.M., Putnam A., Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 2008, 223:371-390.
17. Chen H.D., Fraire A.E., Joris I., Welsh R.M., Selin L.K. Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. Am. J. Pathol. 2003, 163(4):1341-1355.
18. Chicz R.M., Urban R.G., et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 1993, 178:27-47.
19. Chikhlikar P., de Arruda L.B., Gorga J.C., Vignali D.A., Lane W.S., Strominger J.L. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS ONE 2006, 1:e135.
20. Cohen, T., Ardito, M. et al. Unpublished Work.
21. Cole S.T., Brosch R., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393(6685):537-544.
22. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A.J., Chien D.Y., Houghton M., Parham P., Walker C.M. Analysis of a successful immune response against hepatitis C virus. Immunity 1999, 10(4):439-449.
23. Cornberg M., Chen A.T., et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J. Clin. Invest. 2006, 116(5):1443-1456.
24. Couillin I., Culmann-Penciolelli B., Guegan N., Levy J., Guillet J.G., Gomard E. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J. Exp. Med. 1994, 180(3):1129-1134.
25. Cresswell P., Lanzavecchia A. Antigen processing and recognition. Curr. Opin. Immunol. 2001, 13(1):11-12.
26. Crook T., Morgenstern J.P., Crawford L., Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 1989, 8(2):513-519.
27. Curotto de Lafaille M.A., Lafaille J.J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 2009, 30(5):626-635.
28. Daher L.J., Demanga C.G., Prieur E., Catherine Blanc C., Pérignon J., Bouharoun-Tayoun H., Druilhe P. Towards the rational design of a malaria vaccine construct: example of the MSP3 family. Part I: Immunogenicity studies in models. Infect. Immun. 2010, 78(1):477-485.
29. Davenport M.P., Hill A.V. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol. Med. Today 1996, 2(1):38-45.
30. Davenport M.P., Ho Shon I.A., Hill A.V.S. An empirical method for the prediction of T-cell epitopes. Immunogenetics 1995, 42(5):392-397.
31. De Groot A.S., Bosma A., Chinai N., Frost J., Jesdale B.M., Gonzalez M.A., Martin W., Saint-Aubin C. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001, 19(31):4385-4395.
32. De Groot A.S., Jesdale B.M., Szu E., Schafer J.R., Chicz R.M., Deocampo G. An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. AIDS Res. Hum. Retroviruses 1997, 13(7):529-531.
33. De Groot A.S., Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin. Immunol. 2009, 131(2):189-201.
34. De Groot, A.S., Martin, W. et al. Unpublished Work.
35. De Groot, A.S., Martin, W. et al. Unpublished Results.
36. De Groot A.S., Nene V., Hegde N.R., Srikumaran S., Rayner J., Martin W. T cell epitope identification for bovine vaccines: an epitope mapping method for BoLA A-11. Int. J. Parasitol. 2003, 33(5-6):641-653.
37. De Groot A.S., Rivera D.S., McMurry J.A., Buus S., Martin W. Identification of immunogenic HLA-B7 'Achilles' heel' epitopes within highly conserved regions of HIV. Vaccine 2008, 26(24):3059-3071.
38. Delcher A.L., Kasif S., Fleischmann R.D., Peterson J., White O., Salzberg S.L. Alignment of whole genomes. Nucleic Acids Res. 1999, 27(11):2369-2376.
39. DeLeo A., Whiteside T. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev. Vaccines 2008, 7(7):1031-1040.
40. DeLisi C., Berzofsky J.A. T-cell antigenic sites tend to be amphipathic structures. Proc. Natl. Acad. Sci. U.S.A 1985, 82(20):7048-7052.
41. Diamond D.J., York J., Sun J., Wright C.L., Forman S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 1997, 90(5):1751-1767.
42. Duan X., Hisaeda H., et al. The ubiquitin-proteasome system plays essential roles in presenting an 8-mer CTL epitope expressed in APC to corresponding CD8+ T cells. Int. Immunol. 2006, 18(5):679-687.
43. Duraiswamy J., Sherritt M., Thomson S., Tellam J., Cooper L., Connolly G., Bharadwaj M., Khanna R. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003, 101(8):3150-3156.
44. Elliott T., Cerundolo V., Elvin J., Townsend A. Peptide-induced conformational change of the class I heavy chain. Nature 1991, 351(6325):402-406.
45. Falk K., Rotzschke O., Stevanovi S., Jung G., Rammensee H.G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991, 351(6324):290-296.
46. Firat H., Garcia-Pons F., et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 1999, 29(10):3112-3121.
47. Fleckenstein B., Kalbacher H., Muller C., Stoll D., Halder T., Jung G., Weismuller K. New ligands binding to the human leukocyte antigen class II molecule DRB1*0101 based on the activity pattern of an undecapeptide library. Eur. J. Biochem. 1996, 240(1):71-77.
48. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 1993, 178(6):2249-2254.
49. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., Davis M.M., Engleman E.G. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U.S.A 2001, 98(15):8809-8814.
50. Germain R.N., Margulies D.H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 1993, 11:403-450.
51. German R.N., Castellino F., Han R., Reis e Sousa C., Romagnoli P., Sadegh-Nasseri S., Zhong G.M. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunol. Rev. 1996, 151:5-30.
52. Glatman-Freedman A., Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin. Microbiol. Rev. 1998, 11(3):514-532.
53. Gregory S.H., Mott S., Phung J., Lee J., Moise L., McMurry J.A., Martin W., De Groot A.S. Epitope-based vaccination against pneumonic tularemia. Vaccine 2009, 27(39):5299-5306.
54. Gulley J.L. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 2008, 14:3060-3069.
55. Hanke T., Schneider J., Gilbert S.C., Hill A.V., McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998, 16(4):426-435.
56. Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989, 8(12):3905-3910.
57. Hodge J.W., Sabzevari H., Yafal A.G., Gritz L., Lorenz M.G., Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999, 59(22):5800-5807.
58. Hiroi T., Kiyono H., Fujihashi H., McGhee J.R. Quantitation of T-cell cytokine responses by ELISA, ELISPOT, flow cytometry and reverse transcriptase-PCR methods. Immunology of Infection 2002, Academic Press, San Diego. S.H.E. Kaufmann, D. Kabelitz (Eds.).
59. Irvine K., Parkhurt M.R. Recombinant virus vaccination against 'self' antigens using anchor- fixed immunogens. Cancer Res. 1999, 59(11):2536-2540.
60. Ishioka G.Y., Fikes J., et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol. 1999, 162(7):3915-3925.
61. Jesdale B., Deocampo G., Meisell J., Beall J., Marinello M.J., Chicz R.M., De Groot A.S. Matrix-Based Prediction of MHC Binding Peptides: The EpiMatrix Algorithm, Reagent for HIV Research 1997, Vaccines Cold Spring Harbor Press, Cold Spring Harbor, NY.
62. Kew O.M., Wright P.F., Agol V.I., Delpeyroux F., Shimizu H., Nathanson N., Pallansch M.A. Circulating vaccine-derived polioviruses: current state of knowledge. Bull. World Health Organ. 2004, 82(1):16-23.
63. Kim S.K., Cornberg M., Wang X.Z., Chen H.D., Selin L.K., Welsh R.M. Private specificities of CD8T cell responses control patterns of heterologous immunity. J. Exp. Med. 2005, 201(4):523-533.
64. Koenen H.J., Joosten I. Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood 2000, 95(10):3153-3161.
65. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80(5):707-718.
66. La Rosa C., Krishnan R., Markel S., Schneck J.P., Houghten R., Pinilla C., Diamond D.J. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 2001, 97(6):1776-1786.
67. Lechleider R.J., Arlen P.M., Tsang K.Y., Steinberg S.M., Yokokawa J., Cereda V., Camphausen K., Schlom J., Dahut W.L., Gulley J.L. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin. Cancer Res. 2008, 14(16):5284-5291.
68. Leighton J., Sette A., Sidney J., Appella E., Ehrhardt C., Fuchs S., Adorini L. Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. J. Immunol. 1991, 147(1):198-204.
69. Lipford G.B., Hoffman M., Wagner H., Heeg K. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J. Immunol. 1993, 150(4):1212-1222.
70. Livingston B. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J. Immunol. 2002, 168:5499-5506.
71. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001, 19(32):4652-4660.
72. Ljunggren H.G., Stam N.J., et al. Empty MHC class I molecules come out in the cold. Nature 1990, 346(6283):476-480.
73. Mamitsuka H. Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models. Proteins 1998, 33(4):460-474.
74. Man S., Newberg M.H., Crotzer V.L., Luckey C.J., Williams N.S., Chen Y., Huczko E.L., Ridge J.P., Engelhard V.H. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int. Immunol. 1995, 7(4):597-605.
75. McMichael A.J., Phillips R.E. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 1997, 15:271-296.
76. McMurry J.A., Gregory S.H., Moise L., Rivera D., Buus S., De Groot A.S. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 2007, 25(16):3179-3191.
77. Meister G.E., Roberts C.G., Berzofsky J.A., De Groot A.S. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 1995, 13(6):581-591.
78. Missale G., Bertoni R., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 1996, 98(3):706-714.
79. Morris S., Kelley C., Howard A., Li Z., Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000, 18(20):2155-2163.
80. Moudgil K.D., Sercarz E.E., Grewal I.S. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol. Today 1998, 19(5):217-220.
81. Mueller D.L., Jenkins M.K., Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 1989, 7:445-480.
82. Newberg M., Ridge J.P., Vining D.R., Salter R.D., Engelhard V.H. Species specificity in the interaction of CD8 with the a3 domain of MHC class I molecules. J. Immunol. 1992, 149:136-142.
83. Oh S., Terabe M., et al. Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res. 2004, 64:2610-2618.
84. Okazaki T., Terabe M., Catanzaro A.T., Pendleton C.D., Yarchoan R., Berzofsky J.A. Possible therapeutic vaccine strategy against HIV escape from RT inhibitors studied in HLA-A2 transgenic mice. J Virol. 2006, 80:10645-10651.
85. Okazaki T., Pendleton C.D., Lemonnier F., Berzofsky J.A. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J. Immunol. 2003, 171(5):2548-2555.
86. Okazaki T., Pendleton C.D., Sarobe P., Thomas E.K., Iyengar S., Harro C., Schwartz D., Berzofsky J.A. Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J. Immunol. 2006, 176(6):3753-3759.
87. Olsen A.W., Hansen P.R., Holm A., Andersen P. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur. J. Immunol. 2000, 30(6):1724-1732.
88. Oukka M., Manuguerra J.C., Livaditis N., Tourdot S., Riche N., Vergnon I., Cordopatis P., Kosmatopoulos K. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J. Immunol. 1996, 157(7):3039-3045.
89. Palena C., Zhu M., Schlom J., Tsang K.-Y. A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines. Artif. Cells Blood Substit. Immobil. Biotechnol. 2003, 31(2):193-228.
90. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 1994, 152(1):163-175.
91. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J.Immunol. 1996, 157(6):2539-2548.
92. Peng S., Trimble C., He L., Tsai Y.C., Lin C.T., Boyd D.A., Pardoll D., Hung C.F., Wu T.C. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther. 2006, 13(1):67-77.
93. Pinchuk I., Starcher B.C., Livingston B., Tvninnereim A., Wu S., Appella E., Sidney J., Sette A., Wizel B. A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae. J. Immunol. 2005, 174(9):5729-5739.
94. Pogue R.R., Eron J., Frelinger J.A., Matsui M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl. Acad. Sci. U.S.A 1995, 92(18):8166-8170.
95. Rammensee H., Bachmann J., Philipp N., Emmerich N., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50(3-4):213-219.
96. Rammensee H.G., Friede T., Stevanovic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41(4):178-228.
97. Rayner, J. and Martin, W. Unpublished Work.
98. Ressing M.E., Sette A., et al. Human CTL epitopes encoded by human papillomavirus type 16E6 and E7 identified through in vivo and vitro immunogenicity studies of HLA-A* 0201-binding peptides. J. Immunol. 1995, 154(11):5934-5943.
99. Rodriguez F., Whitton J.L. Enhancing DNA immunization. Virology 2000, 268(2):233-238.
100. Rosenberg S.A., Yang J.C., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4(3):321-327.
101. Rosenfeld R., Zheng Q., Vajda S., DeLisi C. Flexible docking of peptides to class I major-histocompatibility-complex receptors. Genet. Anal. 1995, 12(1):1-21.
102. Rothbard J.B., Taylor W.R. A sequence pattern common to T cell epitopes. EMBO J. 1988, 7(1):93-100.
103. Rotzschke O., Falk K., Stevanović S., Jung G., Walden P., Rammensee H.G. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 1991, 21(11):2891-2894.
104. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993, 74(5):929-937.
105. Sadasivan B., Lehner P.J., Ortmann B., Spies T., Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 1996, 5(2):103-114.
106. Salazar E., Zaremba S., Arlen P.M., Tsang K.Y., Schlom J. Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int. J. Cancer 2000, 85(6):829-838.
107. Sarobe P., Pendleton C.D., Akatsuka T., Lau D., Engelhard V.H., Feinstone S.M., Berzofsky J.A. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 1998, 102(6):1239-1248.
108. Schafer J., Jesdale B.M., George J., Kouttab N., De Groot A.S. Prediction of well-conserved HIV-1 ligands using a Matrix-based Algorithm, EpiMatrix. Vaccine. Vaccine 1998, 16(19):1880-1884.
109. Sester M., Gartner B.C., Girndt M., Sester U. Vaccination of the solid organ transplant recipient. Transplant. Rev. (Orlando) 2008, 22(4):274-284.
110. Sette A., Buus S., Appella E., Smith J.A., Chesnut R., Miles C., Colon S.M., Grey H.M. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc. Natl. Acad. Sci. U.S.A 1989, 86(9):3296-3300.
111. Sette A., Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 1998, 10(4):478-482.
112. Sette A., Vitiello A., et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitope. J. Immunol. 1994, 153:5586-5592.
113. Sherman D.R., Voskuil M., Schnappinger D., Liao R., Harrell M.I., Schoolnik G.K. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystalline. Proc. Natl. Acad. Sci. U.S.A 2001, 98(13):7534-7539.
114. Shirai M., Arichi T., Nishioka M., Nomura T., Ikeda K., Kawanishi K., Engelhard V.H., Feinstone S.M., Berzofsky J.A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 1995, 154(6):2733-2742.
115. Sinigaglia F., Hammer J. Defining rules for the peptide-MHC class II interaction. Curr. Opin. Immunol. 1994, 6(1):52-56.
116. Slansky J.E., Rattis F.M., Boyd L.F., Fahmy T., Jaffee E.M., Schneck J., Margulies D.H., Pardoll D.M. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000, 13(4):529-538.
117. Sonnenberg M.G., Belisle J.T. Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect. Immun. 1997, 65(11):4515-4524.
118. Southwood S., Sidney J., Kondo A., del Guercio M.F., Appella E., Hoffman S., Kubo R.T., Chesnut R.W., Grey H.M., Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 1998, 160(7):3363-3373.
119. Spee P., Neefjes J. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 1997, 27(9):2441-2449.
120. Steere A.C., Klitz W., Drouin E.E., Falk B.A., Kwok W.W., Nepom G.T., Baxter-Lowe L.A. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med. 2006, 203(4):961-971.
121. Stille C.J., Thomas L.J., Reyes V.E., Humphreys R.E. Hydrophobic strip-of-helix algorithm for selection of T cell-presented peptides. Mol.Immunol. 1987, 24:1021-1027.
122. Sturniolo T., Bono E., Ding J., Raddrizzani L., Tuereci O., Sahin V., Braxenthaler M., Gallazzi F., Protti M.P., Sinigaglia F., Hammer J. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat. Biotechnol. 1999, 17(6):555-561.
123. Sylvester-Hvid C., Kristensen N., Blicher T., Ferre H., Lauemoller S.L., Wolf X.A., Lamberth K., Nissen M.H., Pedersen L.O., Buus S. Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens 2002, 59(4):251-258.
124. Tangri S., Ishioka G.Y., Huang X., Sidney J., Southwood S., Fikes J., Sette A. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 2001, 194(6):833-846.
125. Thomson S.A., Burrows S.R., Misko I.S., Moss D.J., Coupar B.E., Khanna R. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol. 1998, 72(3):2246-2252.
126. Threlkeld S.C., Wentworth P.A., Kalams S.A., Wilkes B.M., Ruhl D.J., Keogh E., Sidney J., Southwood S., Walker B.D., Sette A. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. J. Immunol. 1997, 159(4):1648-1657.
127. Tian L., Wang H.N., Lu D., Zhang Y.F., Wang T., Kang R.M. The immunoreactivity of a chimeric multi-epitope DNA vaccine against IBV in chickens. Biochem. Biophys. Res. Commun. 2008, 377(1):221-225.
128. Tine J.A., Lanar D.E., et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect. Immun. 1996, 64(9):3833-3844.
129. Tobery T.W., Siliciano R.F. Targeting of HIV-I antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J. Exp. Med. 1997, 185(5):909-920.
130. Tong J.C., Tan T.W., Ranganathan S. Methods and protocols for prediction of immunogenic epitopes. Brief. Bioinformatics 2007, 8(2):96-108.
131. Tourdot S., Oukka M., Manuguerra J.C., Magafa V., Vergnon I., Riche N., Bruley-Rosset M., Cordopatis P., Kosmatopoulos K. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J. Immunol. 1997, 159(5):2391-2398.
132. Tourdot S., Scardino A., Saloustrou E., Gross D., Pascolo S., Cordopatis P., Lemonnier F.A., Kosmatopoulos K. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur. J. Immunol. 2000, 30(12):3411-3421.
133. Trombetta E.S., Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 2005, 23:975-1028.
134. Unanue E.R. Cellular studies on antigen presentation by class II MHC molecules. Curr. Opin. Immunol. 1992, 4(1):63-69.
135. Velders M., Weijzen S., et al. Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine. J. Immunol. 2001, 166(9):5366-5373.
136. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8(7):523-532.
137. Wahlstrom J., Dengjel J., Persson B., Duyar H., Rammensee H.G., Stevanovic S., Eklund A., Weissert R., Grunewald J. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J. Clin. Invest. 2007, 117(11):3576-3582.
138. Wang R., Doolan D.L., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282(5388):476-480.
139. Welsh, R. M. and Selin, L. K. Unpublished Work.
140. Wentworth P.A., Vitiello A., Sidney J., Keogh E., Chestnut R.W., Grey H., Sette A. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 1996, 26(1):97-101.
141. Whitton J.L., Sheng N., Oldstone M.B., McKee T.A. A 'string-of-beads' vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol. 1993, 67(1):348-352.
142. Wille-Reece U., Flynn B.J., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 2006, 203(5):1249-1258.
143. Wilson C.C. Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J. Immunol. 2003, 171:5611-5623.
144. Winslow G.M., Cooper A., Reiley W., Chatterjee M., Woodland D.L. Early T-cell responses in tuberculosis immunity. Immunol. Rev. 2008, 225:284-299.
145. Wu T.C., Guarnieri F.G., Staveley-O'Carroll K.F., Viscidi R.P., Levitsky H.I., Hedrick L., Cho K.R., August J.T., Pardoll D.M. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. U.S.A 1995, 92(25):11671-11675.
146. Yu K., Petrovsky N., Schonbach C., Koh J.Y., Brusic V. Methods for prediction of peptide binding to MHC molecules: a comparative study. Mol. Med. 2002, 8(3):137-148.
147. Zaremba S., Barzaga E., Zhu M., Soares N., Tsang K.Y., Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997, 57(20):4570-4577.
148. Zhang C., Anderson A., DeLisi C. Structural principles that govern the peptide-binding motifs of class I MHC molecules. J. Mol. Biol. 1998, 281(5):929-947.
149. Zhang G.L., Bozic I., Kwoh C.K., August J.T., Brusic V. Prediction of supertype-specific HLA class I binding peptides using support vector machines. J. Immunol. Methods 2007, 320:143-154.
150. Zhu M., Terasawa H., Gulley J., Panicali D., Arlen P., Schlom J., Tsang K. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 2001, 61(9):3725-3734.